FDA
-
-
-
-
-
-
-
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
-
-
-
-
-
-
-
Biogen to present Phase 2 Alzheimer's drug data at AAIC 2026
-
-
-
-
-
-
-
Biogen and Denali discontinue Parkinson's drug after trial fails
-
-
-
-
-
-
-
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on Biogen (BIIB) following FDA approval of HD Spinraza for SMA
-
-
-
-
-
-
-
Biogen to present litifilimab lupus data at dermatology meeting
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $228 at H.C. Wainwright
-
325,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

